Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)

BACKGROUND: Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE: To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as biomarkers of patient outcome following taxane chemotherapy. DESIGN, SETTING, A...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehra, Niven, Dolling, David, Sumanasuriya, Semini, Christova, Rossitza, Pope, Lorna, Carreira, Suzanne, Seed, George, Yuan, Wei, Goodall, Jane, Hall, Emma, Flohr, Penny, Boysen, Gunther, Bianchini, Diletta, Sartor, Oliver, Eisenberger, Mario A., Fizazi, Karim, Oudard, Stephane, Chadjaa, Mustapha, Macé, Sandrine, de Bono, Johann S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090941/
https://www.ncbi.nlm.nih.gov/pubmed/29500065
http://dx.doi.org/10.1016/j.eururo.2018.02.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090941/
https://www.ncbi.nlm.nih.gov/pubmed/29500065
http://dx.doi.org/10.1016/j.eururo.2018.02.013

Ejemplares similares